A Pilot Study of a Novel Multimodality Immuno-Chemotherapy Platform for Patients With Advanced Cutaneous T Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Poly ICLC (Primary) ; Romidepsin (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Adverse reactions
- 24 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 24 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 03 Aug 2017 Status changed from recruiting to active, no longer recruiting.